Related Experiment Videos
Gene therapy for gliomas: p53 and E2F-1 proteins and the target of apoptosis
C Gomez-Manzano1, J Fueyo, F Alameda
1Department of Neuro-Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Abstract:
Current therapy for glioma is suboptimal. The transfer of apoptosis genes to tumors constitutes one of the most promising strategies for cancer gene therapy. We have previously shown that massive apoptosis occurs when wild-type p53 or E2F-1 expression is induced in glioma. However, the mechanism of action and the efficiency in inducing apoptosis of these two proteins are not similar. Adenovirus-mediated p53 gene transfer is ineffective in causing apoptosis in glioma cells that retain wild-type p53 genotype or overexpress the p21 protein. The p16/Rb/E2F pathway is the most frequent target of genetic alterations in gliomas, and therefore constitutes a suitable target for gene therapy strategies. However, the transfer of either the p16 or Rb gene to glioma cells results in cytostatic effect. The E2F-1 protein is able to induce generalized apoptosis in gliomas independently of the p53, p16 or Rb status. In addition, p21- or p16-mediated growth arrest did not protect glioma cells from E2F-1-mediated apoptosis. The apoptotic molecule bax is induced in p53-mediated apoptosis, but bax is not induced in E2F-1-mediated apoptosis in glioma cells. Careful selection of patients may be necessary before designing therapeutic strategies using either p53 or E2F-1 as a therapeutic tools for glioma patients.
Insights
Gene therapy for glioma shows promise. E2F-1 induces apoptosis in glioma cells, unlike p53, offering a potential new treatment strategy for this brain tumor.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Gene Therapy
Background:
- Current glioma therapies are suboptimal.
- Gene therapy, particularly inducing apoptosis, is a promising strategy for glioma treatment.
- The p53 and E2F-1 proteins can induce apoptosis in glioma cells, but their mechanisms and efficiencies differ.
Purpose of the Study:
- To compare the efficacy of p53 and E2F-1 gene transfer in inducing apoptosis in glioma cells.
- To investigate the mechanisms of apoptosis induced by p53 and E2F-1.
- To determine the suitability of p53 and E2F-1 as therapeutic targets for glioma gene therapy.
Main Methods:
- Adenovirus-mediated gene transfer of wild-type p53 and E2F-1 into glioma cells.
- Assessment of apoptosis induction in glioma cells with varying p53, p16, Rb, and p21 statuses.
- Analysis of the expression of apoptotic molecules like bax.
Main Results:
- Adenovirus-mediated p53 gene transfer was ineffective in glioma cells with wild-type p53 or high p21 expression.
- E2F-1 induced generalized apoptosis in gliomas irrespective of p53, p16, or Rb status.
- p21- or p16-mediated growth arrest did not prevent E2F-1-induced apoptosis.
- Bax was induced in p53-mediated apoptosis but not in E2F-1-mediated apoptosis.
Conclusions:
- E2F-1 is a potent inducer of apoptosis in gliomas, functioning independently of common genetic alterations in the p16/Rb/E2F pathway.
- E2F-1 represents a more versatile therapeutic target than p53 for glioma gene therapy.
- Patient selection based on specific genetic profiles may be crucial for optimizing p53 or E2F-1 based glioma therapies.